Apraglutide clinical trials
Apraglutide is named as an intervention in 2 current clinical trials in our UK, USA, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Czechia, Japan, South Korea, Taiwan, Israel, Sweden, Norway, Netherlands, Austria, Canada, Brazil and Australia registers. 1 is recruiting patients now. All registered phases are Phase 3. The lead sponsor is VectivBio AG. The most-studied condition is Short Bowel Syndrome.
Where Apraglutide is approved
All regulators →- 1 EU orphan designation, most recently for treatment of short bowel syndrome (19 Nov 2018, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Patient leaflets for Apraglutide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Apraglutide
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
NCT07742735 · Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
|
Phase 3 | Recruiting | VectivBio AG | UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Austria, Czechia, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel |
|
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
NCT05018286 · Short Bowel Syndrome
|
Phase 3 | Active, closed | VectivBio AG | UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Czechia, Norway, Japan, South Korea, Taiwan, Israel |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Apraglutide
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| VectivBio AG | 2 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Apraglutide trials
How many clinical trials are testing Apraglutide?
2 current trials in our UK, USA, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Czechia, Japan, South Korea, Taiwan, Israel, Sweden, Norway, Netherlands, Austria, Canada, Brazil and Australia registers name Apraglutide as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Apraglutide trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in UK, 1 with sites in USA, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Belgium, 1 with sites in Denmark, 1 with sites in Poland, 1 with sites in Czechia, 1 with sites in Japan, 1 with sites in South Korea, 1 with sites in Taiwan, 1 with sites in Israel, 1 with sites in Netherlands, 1 with sites in Austria, 1 with sites in Canada, 1 with sites in Brazil and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Apraglutide clinical trials?
The lead sponsor is VectivBio AG. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Apraglutide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Apraglutide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Apraglutide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.